Phase 3
N=416
PCM Cervical Disc System
Radiculopathy · Myelopathy
Bottom Line
View on ClinicalTrials.gov: NCT00578812 ↗Enrolled (actual)
416
Serious AEs
30.9%
Results posted
Feb 2013
Primary outcome: Primary: Individual Patient Overall Success — 142; 98 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Anterior Cervical Discectomy and Fusion (ACDF) (Device); PCM Cervical Disc (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- NuVasive
- Primary completion
- Mar 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Individual Patient Overall Success |
142; 98 | — |
| SECONDARY Neck Pain Visual Analog Scale |
139; 113 | — |
| SECONDARY Mean Neck Pain Visual Analog Scale |
26.1; 30.4 | — |
| SECONDARY Worst Arm Pain Visual Analog Scale |
148; 113 | — |
| SECONDARY Mean Worst Arm Pain Visual Analog Scale |
24.9; 27.5 | — |
| SECONDARY Clinically Significant Improvement on Neck Disability Index (NDI) |
149; 114 | — |
| SECONDARY Clinically Significant Improvement on Neck Disability Index (NDI) |
149; 114 | — |
| SECONDARY Mean Neck Disability Index (NDI) |
21.8; 25.5 | — |
| SECONDARY Clinically Significant Improvement on SF-36 Physical Component Summary (PCS) |
133; 98 | — |
| SECONDARY Mean SF-36 Physical Component Summary (PCS) |
46.6; 45.0 | — |
| SECONDARY Clinically Significant Improvement on SF-36 Mental Component Summary (MCS) |
87; 75 | — |
| SECONDARY Mean SF-36 Mental Component Summary (MCS) |
50.3; 49.3 | — |
| SECONDARY Dysphagia for Swallowing |
8.8; 12.1 | — |
| SECONDARY Patient Satisfaction |
82.8; 81.4 | — |
| SECONDARY Nurick's Classification of Disability (Myelopathy) |
185; 148 | — |
| SECONDARY Flexion/Extension Range of Motion at the Operative Level |
5.7; 0.8 | — |
Summary
The PCM Cervical Disc was studied in a prospective, multicenter, randomized FDA-approved investigational device exemption (IDE) clinical trial conducted in the United States to evaluate longitudinal outcomes over 2 years comparatively between the PCM Cervical Disc and anterior cervical discectomy and fusion (ACDF) with allograft and plate. Patients with adjacent or non-adjacent prior fusion were allowed. A total of 416 patients with a degenerated cervical disc at one level from C3-C4 to C7-T1 were enrolled in the clinical trial and 403 were treated. Patients were randomly assigned to be treated either with the PCM Cervical Disc or ACDF.
Eligibility Criteria
Inclusion Criteria
- Age 18-65 years;
- Diagnosis of radiculopathy or myelopathy of the cervical spine between C3-4 and C7-T1;
- Symptomatic at only one level from C3-C4 to C7-T1;
- Unresponsive to non-operative treatment for six weeks, or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of conservative treatment;
- Baseline NDI score of ≥30/100;
- Radiographically determined pathology at level to be treated correlating to primary symptoms, including at least one of the following: decreased disc height, degenerative spondylosis on CT or MRI, or disc herniation;
- Appropriate for treatment using an anterior surgical approach, including having no more than one previous anterior surgical approach to the cervical spine;
- Ability and willingness to comply with follow-up regimen; and
- Written informed consent given by subject or subject's legally authorized representative.
Exclusion Criteria
- Infection at the site of surgery;
- History of, or anticipated treatment for, active systemic infection, including HIV infection or hepatitis C;
- Prior attempted or completed cervical spine surgery, except (1) laminoforaminotomy with less than one-third facetectomy at any level, or (2) a successful single-level anterior cervical fusion;
- More than one immobile vertebral level between C1-T1 from any cause, including but not limited to congenital abnormalities, osteoarthritic "spontaneous" fusions, and prior cervical spinal fusions;
- Previous trauma to the C3-T1 levels resulting in significant bony or disco-ligamentous cervical spine injury;
- Axial neck pain in the absence of other symptoms of radiculopathy or myelopathy justifying the need for surgical intervention;
- Radiographic confirmation of severe facet joint disease or degeneration.
- Osteoporosis:
- Severe diabetes mellitus requiring daily insulin management;
- Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
- Tumor as source of symptoms;
- Symptomatic DDD or significant cervical spondylosis at two or more levels;
- Known or suspected allergy to cobalt, chromium, molybdenum, titanium, or polyethylene;
- Severe myelopathy to the extent that the patient is wheelchair bound;
- Pregnant (verified in patients of childbearing potential by a negative urine pregnancy test when preadmission testing is obtained), or interested in becoming pregnant during the duration of the study;
- Autoimmune disorders that impact the musculoskeletal system (e.g., lupus, rheumatoid arthritis; ankylosing spondylitis);
- Spinal axis disease (thoracic or lumbar) to the extent that surgical consideration is likely anticipated within 6 months after the cervical randomized procedure;
- Other degenerative joint disease (e.g. shoulder, hip, knee) to the extent that surgical consideration is likely anticipated within 6 months after the cervical randomized procedure;
- Previous spine surgery within the 6 months preceding the cervical randomized procedure;
- Current or recent history of substance abuse (drug or alcohol);
- Morbid obesity, defined as body mass index ("BMI") > 40 or more than 100 lbs. over ideal body weight;
- Currently using, or planning to use, bone growth stimulators in the cervical spine;
- Use of any other investigational drug or medical device within the last 30 days prior to surgery
- Currently a prisoner; or
- Currently pursuing personal litigation related to the neck or cervical spine injury; however, involvement in worker's compensation related litigation is not a required exclusion.
Data sourced from ClinicalTrials.gov (NCT00578812). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.